AHA Scientific Sessions 2024 Late-Breaking and Featured Science Collection
Published: 29 October 2024
-
Views:
1598
-
Likes:
7
-
Views:
1598
-
Likes:
7
-
29m 32s -
18m 41s -
17m 22sPart 2 | Session 3 SUMMIT: Tirzepatide in Patients with HFpEF and Obesity -
16m 57sPart 2 | Session 4 FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk -
22m 30s
-
6m 17s -
3m 53s -
7m 19sPart 3 | Session 3 Mavacamten: Real-World Experience from 22 Months of the REMS Program -
10m 31s
-
Part 4 Coming Soon
Overview
Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.
- To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
- Watch out for the Late-Breaker Discussions with Dr Harriette Van Spall for key clinical trial data and its implications for future research.
- Our concise Expert Interviews provide key data, study designs and take-home messages from select faculty.
- Don't miss the key take aways from our Highlights series.
More from this programme
Part 1
View From the Thoraxcenter
Part 2
Late-Breaker Discussions with Dr Harriette Van Spall
Part 3
Expert Interviews
Part 4
Highlights
| 1 session | |
| Coming Soon | Watch now |
About the episode
Explore the cardiovascular breakthroughs shaping AHA 2024!
Join renowned experts Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) as they preview the most impactful late-breaking studies poised to make waves at this year’s AHA Conference. Dive into their expert analysis and gain key insights into the studies that are set to drive the future of cardiovascular care.
Trials discussed in detail include:
CLEAR-SYNERGY (01:01 - 03:45)
SELECT (03:45 - 04:47)
SUMMIT (04:47 - 08:28)
YELLOW III (08:28 - 11:05)
AMULET IDE (11:05 - 12:25)
VALOR-HCM (12:25 - 13:39)
Stay tuned for Radcliffe Cardiology's in-depth coverage of these and other pivotal trials from AHA Conference 2024.
Faculty Biographies
Joost Daemen
Interventional Cardiologist
Dr Joost Daemen is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center. He is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.
Nicolas M Van Mieghem
Medical Director
Prof Nicolas Maria Van Mieghem is an Interventional cardiologist at Thoraxcenter, Erasmus MC, Rotterdam, NL decided to pursue a career that would help others. “I enjoy the feeling of being able to help someone or do something important for them". His father was a general cardiologist and one of his biggest influences early in his career.
Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
His current research focuses on cerebral embolic protection during TAVI and the search for improved…
Comments